Autonomix Medical (NASDAQ: AMIX) restores Nasdaq minimum bid price compliance
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Autonomix Medical, Inc. reports that it has regained compliance with Nasdaq’s minimum bid price requirement for listing on the Nasdaq Capital Market. The company had previously received a Nasdaq deficiency notice on January 14, 2026 after its common stock closed below $1.00 per share for 30 consecutive business days. Nasdaq informed Autonomix on July 9, 2026 that the closing bid price was at or above $1.00 per share for 10 consecutive business days from June 24, 2026 through July 8, 2026, restoring compliance with Nasdaq Listing Rule 5550(a)(2). Nasdaq has indicated the matter is closed.
Positive
- None.
Negative
- None.
Insights
Autonomix restored Nasdaq bid-price compliance, removing an immediate delisting risk.
Autonomix Medical was under a Nasdaq bid-price deficiency after its stock traded below $1.00 for 30 consecutive business days, triggering Nasdaq Listing Rule 5550(a)(2). On July 9, 2026, Nasdaq confirmed the stock closed at or above $1.00 for 10 straight business days, restoring compliance.
This outcome keeps the shares listed on the Nasdaq Capital Market without additional remediation steps under the Bid Price Rule. It removes one source of near-term listing uncertainty, though the company must continue meeting Nasdaq’s ongoing price and other quantitative standards.
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
Minimum bid price requirement: $1.00 per share
Non-compliance period trigger: 30 consecutive business days
Compliance confirmation window: 10 consecutive business days
+2 more
5 metrics
Minimum bid price requirement
$1.00 per share
Nasdaq Listing Rule 5550(a)(2) minimum closing bid price for continued listing
Non-compliance period trigger
30 consecutive business days
Closing bid price below $1.00 per share that led to the January 14, 2026 deficiency letter
Compliance confirmation window
10 consecutive business days
Closing bid price at or above $1.00 per share from June 24, 2026 through July 8, 2026
Deficiency notice date
January 14, 2026
Date Autonomix received Nasdaq bid-price deficiency letter
Compliance letter date
July 9, 2026
Date Nasdaq notified Autonomix that it regained compliance and closed the matter
Key Terms
Nasdaq Capital Market, Nasdaq Listing Rule 5550(a)(2), Bid Price Rule, Emerging growth company
4 terms
Nasdaq Capital Market financial
"minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market"
The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.
Nasdaq Listing Rule 5550(a)(2) regulatory
"minimum $1.00 per share requirement for continued inclusion ... pursuant to Nasdaq Listing Rule 5550(a)(2)"
Bid Price Rule regulatory
"minimum $1.00 per share requirement ... (the “Bid Price Rule”)"
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
What did Autonomix Medical (AMIX) announce regarding its Nasdaq listing status?
Autonomix Medical announced it has regained compliance with Nasdaq’s minimum bid price requirement, so its common stock remains listed on the Nasdaq Capital Market and Nasdaq has closed the deficiency matter.
Why was Autonomix Medical (AMIX) previously non-compliant with Nasdaq rules?
On January 14, 2026, Autonomix received a Nasdaq deficiency letter because its stock’s closing bid price was below $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).
How did Autonomix Medical (AMIX) regain compliance with the Nasdaq Bid Price Rule?
Autonomix regained compliance after its common stock maintained a closing bid price of $1.00 per share or higher for 10 consecutive business days from June 24, 2026 through July 8, 2026, as confirmed by Nasdaq.
What specific Nasdaq rule applied to Autonomix Medical (AMIX)’s bid price deficiency?
The situation involved Nasdaq Listing Rule 5550(a)(2), often called the Bid Price Rule, which requires a minimum $1.00 per share closing bid price for continued listing on the Nasdaq Capital Market.
Is the Nasdaq bid price compliance issue for Autonomix Medical (AMIX) still open?
No. Nasdaq’s staff informed Autonomix on July 9, 2026 that the company is again in compliance with the Bid Price Rule and that the matter is closed.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 9, 2026
(Exact name of registrant as specified in its charter)
|
|
|
|
|
(State or other jurisdiction of
incorporation or organization)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (713 ) 588-6150
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of Each Class
|
Trading Symbol(s)
|
Name of Each Exchange on which Registered
|
|
|
|
The
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events
As previously reported, on January 14, 2026, Autonomix Medical, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the previous 30 consecutive business days, the closing bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). The deficiency letter did not result in the immediate delisting of the Company’s common stock from the Nasdaq Capital Market.
On July 9, 2026, the Company received a letter from the Staff notifying the Company that it had regained compliance with the Bid Price Rule as a result of the closing bid price of the Company’s common stock being at or above $1.00 per share for the 10 consecutive business days from June 24, 2026 through July 8, 2026. Accordingly, the letter indicated the Company is in compliance with the Bid Price Rule and the matter is closed.
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
AUTONOMIX MEDICAL, INC.
|
|||
|
By:
|
/s/ Trent Smith
|
||
|
Trent Smith
|
|||
|
Chief Financial Officer
|
|||
Dated: July 10, 2026